Chunfang Hao
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Dynamic changes in peripheral B and NK cells reflect treatment response in breast cancer subtypes.
Journal: Discover oncology
Published: December 03, 2025
Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study.
Journal: Frontiers in pharmacology
Published: November 30, 2025
Chinese Society of Clinical Oncology breast cancer expert consensus on the diagnosis and treatment of breast cancer brain metastasis (2025).
Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: August 12, 2025
Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 31, 2025
DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer.
Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: June 27, 2025
Recent advances in systemic treatment for HER2-negative breast cancer with brain metastases.
Journal: Critical reviews in oncology/hematology
Published: June 19, 2025
Dalpiciclib plus fulvestrant and pyrotinib in HR+/HER2-low advanced breast cancer after progression on CDK4/6 inhibition (DapPLE-HER): a Bayesian optimal phase II study.
Journal: International journal of surgery (London, England)
Published: June 19, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: February 24, 2025
Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: December 25, 2024
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer.
Journal: Cancer treatment reviews
Published: October 09, 2024
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024.
Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: June 01, 2024
Last Updated: 09/26/2026